Distribution of product usage since birth by product type and severity of hemophilia among ITs (n = 670)
| Type of product . | HA . | HB . | ||||
|---|---|---|---|---|---|---|
| 537 had at least 1 product type prescribed . | 133 had at least 1 product type prescribed . | |||||
| Mild . | Moderate . | Severe . | Mild . | Moderate . | Severe . | |
| n = 60 (ITs in this disease category with any product use) . | n = 82 (ITs in this disease category with any product use) . | n = 395 (ITs in this disease category with any product use) . | n = 13 (ITs in this disease category with any product use) . | n = 47 (ITs in this disease category with any product use) . | n = 73 (ITs in this disease category with any product use) . | |
| Clotting factor (recombinant and pd) | 34 (56.7%) | 53 (64.6%) | 226 (57.2%) | 9 (69.2%) | 38 (80.9%) | 48 (65.8%) |
| Emicizumab | 0 (0.0%) | ∗ | 28 (7.1%) | N/A | N/A | N/A |
| Other (including bypassing agent, aminocaproic acid) or multiple products | 26 (43.3%) | ∗ | 141 (35.7%) | ∗ | 9 (19.1%) | 25 (34.2%) |
| Type of product . | HA . | HB . | ||||
|---|---|---|---|---|---|---|
| 537 had at least 1 product type prescribed . | 133 had at least 1 product type prescribed . | |||||
| Mild . | Moderate . | Severe . | Mild . | Moderate . | Severe . | |
| n = 60 (ITs in this disease category with any product use) . | n = 82 (ITs in this disease category with any product use) . | n = 395 (ITs in this disease category with any product use) . | n = 13 (ITs in this disease category with any product use) . | n = 47 (ITs in this disease category with any product use) . | n = 73 (ITs in this disease category with any product use) . | |
| Clotting factor (recombinant and pd) | 34 (56.7%) | 53 (64.6%) | 226 (57.2%) | 9 (69.2%) | 38 (80.9%) | 48 (65.8%) |
| Emicizumab | 0 (0.0%) | ∗ | 28 (7.1%) | N/A | N/A | N/A |
| Other (including bypassing agent, aminocaproic acid) or multiple products | 26 (43.3%) | ∗ | 141 (35.7%) | ∗ | 9 (19.1%) | 25 (34.2%) |
Categorical data are presented as n (%).
N/A, not applicable.
Known fields with N of greater than 0 but less than 5 have been suppressed to protect patient confidentiality.